Screener
Ginkgo Bioworks DNA Reportable Segment — Stock-Based Comp
Similar metrics at other companies
Other financials
Where this comes from
Reported directly by Ginkgo Bioworks in its filing.
Tagged under the XBRL concept us-gaap:EmployeeBenefitsAndShareBasedCompensation.
The source filing: Ginkgo Bioworks’s 10-Q, filed August 6, 2026.
- Filed
- Aug 6, 2026, 4:09 PM EDT
- Fiscal quarter
- Q2 FY2026
- Calendar quarter
- Q2 2026
- Accession
- 0001628280-26-054298
| Line item | Three Months Ended June 30, 2026 | 2025 | Six Months Ended June 30, 2026 | 2025 |
|---|---|---|---|---|
| Cost of other revenue (1) | 1,472 | 3,865 | 4,144 | 6,986 |
| Research and development (1) | 30,433 | 31,065 | 60,538 | 79,735 |
| General and administrative (1) | 11,108 | 15,986 | 23,831 | 35,639 |
| Stock-based compensation (2) | 8,037 | 18,770 | 24,745 | 36,483 |
| Depreciation and amortization | 12,315 | 15,249 | 25,114 | 30,071 |
| Restructuring charges (3) | — | 3,566 | — | 8,032 |
| Carrying cost of excess space (net of sublease income) (4) | 14,233 | 12,413 | 30,074 | 24,088 |
| Merger and acquisition related expense (income) (5) | 1,106 | (3,617) | 1,106 | (4,535) |
Item 1. Financial Statements (Unaudited)
FAQ
- What is Ginkgo Bioworks's reportable segment — stock-based comp?
- Ginkgo Bioworks (DNA) reported reportable segment — stock-based comp of $8.04M in Q2 2026.
- What does reportable segment — stock-based comp mean?
- This represents the non-cash expense recognized for equity-based awards granted to employees within a specific business segment. It is an essential component for understanding the true cost of talent acquisition and retention relative to the segment's operational output.
Ask your AI about Ginkgo Bioworks's reportable segment — stock-based comp.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude